Theriva Biologics Gains Orphan Drug Status for VCN-01
Company Announcements

Theriva Biologics Gains Orphan Drug Status for VCN-01

Theriva Biologics ( (TOVX) ) has issued an update.

Theriva Biologics has announced that the European Commission granted orphan medicinal product designation to its leading candidate VCN-01 for treating retinoblastoma, highlighting the urgent need for new therapies. This designation, following similar recognition by the FDA, underscores VCN-01’s potential to transform treatment options, offering significant benefits to patients by enhancing chemotherapy effectiveness and improving immune response against tumors.

For a thorough assessment of TOVX stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyTheriva Biologics reports Q3 EPS ($6.81) vs. ($4.85) last year
Sheryl Sheth3 Penny Stocks to Watch Now, 11/5/24
TipRanks Auto-Generated NewsdeskTheriva Biologics Expands Stock Plans and Share Authority
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App